
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3652978/publications.pdf Version: 2024-02-01



IAMES M HOFEMAN

#	Article	IF	CITATIONS
1	Pharmacists Leading the Way to Precision Medicine: Updates to the Core Pharmacist Competencies in Genomics. American Journal of Pharmaceutical Education, 2022, 86, 8634.	0.7	21
2	Why do subcutaneous ports get stuck? A case-control study. Journal of Pediatric Surgery, 2022, 57, 229-233.	0.8	3
3	ASHP Statement on the Pharmacist's Role in Clinical Pharmacogenomics. American Journal of Health-System Pharmacy, 2022, 79, 704-707.	0.5	37
4	Advancing pharmacogenomics into practice. American Journal of Health-System Pharmacy, 2022, 79, 603-604.	0.5	1
5	National trends in prescription drug expenditures and projections for 2022. American Journal of Health-System Pharmacy, 2022, 79, 1158-1172.	0.5	22
6	An adaptive, asymptomatic SARS-CoV-2 workforce screening program providing real-time, actionable monitoring of the COVID-19 pandemic. PLoS ONE, 2022, 17, e0268237.	1.1	3
7	Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. Annual Review of Genomics and Human Genetics, 2022, 23, 449-473.	2.5	15
8	A nucleic acid amplification testâ€based strategy does not help inform return to work for healthcare workers with COVIDâ€19. Influenza and Other Respiratory Viruses, 2022, 16, 851-853.	1.5	1
9	The Effects of the Second Victim Phenomenon on Work-Related Outcomes: Connecting Self-Reported Caregiver Distress to Turnover Intentions and Absenteeism. Journal of Patient Safety, 2021, 17, 195-199.	0.7	87
10	Expanding evidence leads to new pharmacogenomics payer coverage. Genetics in Medicine, 2021, 23, 830-832.	1.1	49
11	ASHP Foundation Pharmacy Forecast 2021: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2021, 78, 472-497.	0.5	12
12	National trends in prescription drug expenditures and projections for 2021. American Journal of Health-System Pharmacy, 2021, 78, 1294-1308.	0.5	32
13	Approaches to assessing the provider experience with clinical pharmacogenomic information: a scoping review. Genetics in Medicine, 2021, 23, 1589-1603.	1.1	3
14	Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA - Journal of the American Medical Association, 2021, 325, 2500.	3.8	83
15	Associations of job demands and patient safety event involvement on burnout among a multidisciplinary group of pediatric hematology/oncology clinicians. Pediatric Blood and Cancer, 2021, 68, e29214.	0.8	5
16	Never Enough Time: Mixed Methods Study Identifies Drivers of Temporal Demand That Contribute to Burnout Among Physicians Who Care for Pediatric Hematology-Oncology Patients. JCO Oncology Practice, 2021, 17, e958-e971.	1.4	4
17	Validation of the Second Victim Experience and Support Tool-Revised in the Neonatal Intensive Care Unit. Journal of Patient Safety, 2021, 17, 531-540.	0.7	22
18	The Clinical Pharmacogenetics Implementation Consortium: 10ÂYears Later. Clinical Pharmacology and Therapeutics, 2020, 107, 171-175.	2.3	207

#	Article	IF	CITATIONS
19	ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2020, 77, 84-112.	0.5	29
20	Improving Patient Handoffs and Transitions through Adaptation and Implementation of I-PASS Across Multiple Handoff Settings. Pediatric Quality & Safety, 2020, 5, e323.	0.4	32
21	National trends in prescription drug expenditures and projections for 2020. American Journal of Health-System Pharmacy, 2020, 77, 1213-1230.	0.5	34
22	Biomedical Data Science and Informatics Challenges to Implementing Pharmacogenomics with Electronic Health Records. Annual Review of Biomedical Data Science, 2020, 3, 289-314.	2.8	10
23	Preemptively Precise: Returning and Updating Pharmacogenetic Test Results to Realize the Benefits of Preemptive Testing. Clinical Pharmacology and Therapeutics, 2019, 106, 942-944.	2.3	17
24	Priorities for Pediatric Patient Safety Research. Pediatrics, 2019, 143, .	1.0	33
25	Accelerating Improvement in Children's Healthcare Through Quality Improvement Collaboratives: a Synthesis of Recent Efforts. Current Treatment Options in Pediatrics, 2019, 5, 111-130.	0.2	11
26	National trends in prescription drug expenditures and projections for 2019. American Journal of Health-System Pharmacy, 2019, 76, 1105-1121.	0.5	29
27	Optimizing Drug-Drug Interaction Alerts Using a Multidimensional Approach. Pediatrics, 2019, 143, .	1.0	14
28	Developing Evidence for New Patient Safety Bundles Through Multihospital Collaboration. Journal of Patient Safety, 2019, Publish Ahead of Print, e1576-e1584.	0.7	8
29	ASHP Foundation Pharmacy Forecast 2019: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2019, 76, 71-100.	0.5	14
30	Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genetics in Medicine, 2019, 21, 1224-1232.	1.1	57
31	ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2018, 75, 23-54.	0.5	19
32	Using EHR Data to Detect Prescribing Errors in Rapidly Discontinued Medication Orders. Applied Clinical Informatics, 2018, 09, 082-088.	0.8	5
33	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics, 2018, 19, 847-860.	0.6	53
34	The Second Victim Experience and Support Tool: Validation of an Organizational Resource for Assessing Second Victim Effects and the Quality of Support Resources. Journal of Patient Safety, 2017, 13, 93-102.	0.7	159
35	Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. American Journal of Health-System Pharmacy, 2017, 74, 409-415.	0.5	14
36	ASHP Foundation Pharmacy Forecast 2017: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2017, 74, 27-53.	0.5	10

#	Article	IF	CITATIONS
37	Pharmacogenomics competencies in pharmacy practice: A blueprint for change. Journal of the American Pharmacists Association: JAPhA, 2017, 57, 120-125.	0.7	58
38	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine, 2017, 19, 215-223.	1.1	410
39	Leveraging precision medicine to mitigate medication-safety challenges. American Journal of Health-System Pharmacy, 2017, 74, 2031-2032.	0.5	0
40	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. American Journal of Health-System Pharmacy, 2016, 73, 1977-1985.	0.5	79
41	Patient Safety Culture and the Second Victim Phenomenon: Connecting Culture to Staff Distress in Nurses. Joint Commission Journal on Quality and Patient Safety, 2016, 42, 377-AP2.	0.4	89
42	Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 796-801.	2.2	83
43	Integrating pharmacogenomics into electronic health records with clinical decision support. American Journal of Health-System Pharmacy, 2016, 73, 1967-1976.	0.5	118
44	Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. Pediatrics, 2016, 138, .	1.0	71
45	The genomic CDS sandbox: An assessment among domain experts. Journal of Biomedical Informatics, 2016, 60, 84-94.	2.5	4
46	Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, e138-e141.	2.2	30
47	ASHP Guidelines on Preventing Medication Errors with Chemotherapy and Biotherapy. American Journal of Health-System Pharmacy, 2015, 72, e6-e35.	0.5	72
48	Preventing chemotherapy errors: Updating guidelines to meet new challenges. American Journal of Health-System Pharmacy, 2015, 72, 668-669.	0.5	2
49	Accuracy of annual prescription drug expenditure forecasts in <i>AJHP</i> . American Journal of Health-System Pharmacy, 2015, 72, 1642-1648.	0.5	3
50	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annual Review of Pharmacology and Toxicology, 2015, 55, 89-106.	4.2	442
51	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217.	0.7	341
52	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update. Clinical Pharmacology and Therapeutics, 2014, 95, 499-500.	2.3	123
53	Development and use of active clinical decision support for preemptive pharmacogenomics. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, e93-e99.	2.2	186
54	Economic Evaluations of Clinical Pharmacy Services: 2006–2010. Pharmacotherapy, 2014, 34, 771-793.	1.2	148

#	Article	IF	CITATIONS
55	National trends in prescription drug expenditures and projections for 2014. American Journal of Health-System Pharmacy, 2014, 71, 482-499.	0.5	62
56	Adverse Drug Event Detection in Pediatric Oncology and Hematology Patients: Using Medication Triggers to Identify PatientÂHarm in a Specialized Pediatric Patient Population. Journal of Pediatrics, 2014, 165, 447-452.e4.	0.9	30
57	PG4KDS: A model for the clinical implementation of preâ€emptive pharmacogenetics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 45-55.	0.7	221
58	Biosimilars: Implications for health-system pharmacists. American Journal of Health-System Pharmacy, 2013, 70, 2004-2017.	0.5	54
59	Posaconazole Therapeutic Drug Monitoring in Pediatric Patients and Young Adults with Cancer. Annals of Pharmacotherapy, 2013, 47, 976-983.	0.9	50
60	National survey on the effect of oncology drug shortages on cancer care. American Journal of Health-System Pharmacy, 2013, 70, 609-617.	0.5	90
61	The safety of cefepime and ceftazidime in pediatric oncology patients. Pediatric Blood and Cancer, 2013, 60, 806-809.	0.8	7
62	Projecting future drug expenditures in U.S. nonfederal hospitals and clinics—2013. American Journal of Health-System Pharmacy, 2013, 70, 525-539.	0.5	19
63	Implications of the FDA Draft Guidance on Biosimilars for Clinicians: What We Know and Don't Know. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 368-372.	2.3	5
64	Projecting future drug expenditures—2012. American Journal of Health-System Pharmacy, 2012, 69, 405-421.	0.5	59
65	A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clinical Pharmacology and Therapeutics, 2012, 92, 563-566.	2.3	94
66	Safe and Successful Implementation of CPOE for Chemotherapy at a Children's Cancer Center. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-36-S-50.	2.3	26
67	NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-22.	2.3	118
68	Development and implementation of a pharmacist-managed clinical pharmacogenetics service. American Journal of Health-System Pharmacy, 2011, 68, 143-150.	0.5	128
69	Projecting future drug expenditures—2011. American Journal of Health-System Pharmacy, 2011, 68, 921-932.	0.5	34
70	NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-7-S-27.	2.3	18
71	Efficacy and Safety of Cefepime in Pediatric Patients: A Systematic Review and Meta-Analysis. Journal of Pediatrics, 2010, 157, 490-495.e1.	0.9	17
72	Projecting future drug expenditures—2010. American Journal of Health-System Pharmacy, 2010, 67, 919-928.	0.5	19

JAMES M HOFFMAN

#	Article	IF	CITATIONS
73	Risk evaluation and mitigation strategies: Challenges and opportunities for health-system pharmacists. American Journal of Health-System Pharmacy, 2010, 67, 1547-1554.	0.5	10
74	Intravenous Zanamivir for Oseltamivir-Resistant 2009 H1N1 Influenza. New England Journal of Medicine, 2010, 362, 88-89.	13.9	128
75	Transparent and reproducible reports of economic evaluations of clinical pharmacy services: A goal for the future?. American Journal of Health-System Pharmacy, 2009, 66, 442-443.	0.5	3
76	Projecting future drug expenditures—2009. American Journal of Health-System Pharmacy, 2009, 66, 237-257.	0.5	36
77	Economic Evaluations of Clinical Pharmacy Services: 2001–2005. Pharmacotherapy, 2009, 29, 128-128.	1.2	84
78	Projecting future drug expenditures—2008. American Journal of Health-System Pharmacy, 2008, 65, 234-253.	0.5	32
79	Projecting future drug expenditures—2007. American Journal of Health-System Pharmacy, 2007, 64, 298-314.	0.5	27
80	Projecting future drug expenditures—2006. American Journal of Health-System Pharmacy, 2006, 63, 123-138.	0.5	26
81	Projecting future drug expenditures—2005. American Journal of Health-System Pharmacy, 2005, 62, 149-167.	0.5	32
82	Pharmacy residency training in academic medical centers. American Journal of Health-System Pharmacy, 2004, 61, 2528-2533.	0.5	18
83	Patent expiration for lansoprazole. American Journal of Health-System Pharmacy, 2004, 61, 2253-2253.	0.5	0
84	Projecting future drug expenditures—2004. American Journal of Health-System Pharmacy, 2004, 61, 145-158.	0.5	26
85	Medication Errors Caused by Confusion of Drug Names. Drug Safety, 2003, 26, 445-452.	1.4	83
86	Projecting future drug expenditures—2003. American Journal of Health-System Pharmacy, 2003, 60, 137-149.	0.5	25
87	Quality improvement knowledge in pediatric hematology/oncology physicians: A need for improved education. Pediatric Blood and Cancer, 0, , .	0.8	0